他克莫司
伊马替尼
最大值
药代动力学
药理学
医学
CYP3A4型
钙调神经磷酸酶
药物相互作用
化学
内科学
移植
髓系白血病
新陈代谢
细胞色素P450
作者
Naling Fan,Teng Guo,Liying Du,Mingfeng Liu,Xinran Chen
出处
期刊:Current Drug Metabolism
[Bentham Science]
日期:2024-12-23
卷期号:26
标识
DOI:10.2174/0113892002319356241210073350
摘要
Tacrolimus, a calcineurin inhibitor (CNI), is the first-line treatment for chronic myeloid leukemia (CML) and advanced gastrointestinal stromal tumors (GIST). Imatinib and tacrolimus are both substrates of the hepatic enzymes CYP3A4/5 and efflux transporter P-gp, so drug-drug interactions may occur during their co-administration treatment. Therefore, this study aimed to evaluate the pharmacokinetic interaction between imatinib and tacrolimus in rats.
科研通智能强力驱动
Strongly Powered by AbleSci AI